Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation.

RATIONALE The role of pulmonary function before stem cell transplant as a potential risk factor for the development of early post-transplant respiratory failure and mortality is controversial. METHODS We conducted a retrospective analysis of the pretransplant pulmonary function of 2,852 patients who received their transplant between 1990 and 2001. MEASUREMENTS Pretransplant FEV(1), FVC, total lung capacity (TLC), diffusing capacity of carbon monoxide (DL(CO)), and the alveolar-arterial oxygen tension difference P(A-a)O(2) were measured and assessed for association with development of early respiratory failure and mortality in Cox proportional hazard logistic models. MAIN RESULTS In multivariate analyses, progressive decrease of all lung function parameters was associated with a stepwise increase in risk of developing early respiratory failure and mortality when assessed in independent models. On the basis of a significant correlation between FEV(1) and FVC (r = 0.81), FEV(1) and TLC (r = 0.61), and FVC and TLC (r = 0.80), and a lack of correlation between FEV(1) and DL(CO), we developed a pretransplant lung function score based on pretransplant FEV(1) and DL(CO) to determine the extent of pulmonary compromise before transplant. Multivariate analysis indicated that higher pretransplant lung function scores are associated with a significant increased risk for developing early respiratory failure (category II hazard ratio [HR], 1.4; category III HR, 2.2; category IV HR, 3.1; p < 0.001) and death (category II HR, 1.2; category III HR, 2.2; category IV HR, 2.7; p < 0.005). CONCLUSIONS These results suggest that not only does compromised pretransplant lung function contribute to the risk for development of early respiratory failure and mortality but this risk may be estimated before transplant by grading the extent of FEV(1) and DL(CO) compromise.

[1]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.

[2]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[3]  M. Maris,et al.  Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  D. Madtes,et al.  Pulmonary function testing prior to hematopoietic stem cell transplantation , 2005, Bone Marrow Transplantation.

[5]  C. Flowers,et al.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. , 2004, Blood.

[6]  M. Flowers,et al.  Implications of early airflow decline after myeloablative allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.

[7]  S. Heckbert,et al.  Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. , 2003, American journal of respiratory and critical care medicine.

[8]  H. Deeg,et al.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. , 2002, Blood.

[9]  D. Schrag,et al.  Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. , 2001, Blood.

[10]  R. Soiffer,et al.  Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  N. Ueno,et al.  Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. , 1999, Blood.

[12]  直子 加藤,et al.  Graft-Versus-host Disease , 1999 .

[13]  S. Goldberg,et al.  Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Niland,et al.  Pretransplant pulmonary function predicts cytomegalovirus-associated interstitial pneumonia following bone marrow transplantation. , 1992, Chest.

[15]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[16]  L. Thompson,et al.  Evaluation of pulmonary complications after bone marrow transplantation: the role of pretransplant pulmonary function tests. , 1992, Bone marrow transplantation.

[17]  S. Crawford,et al.  Predictive value of pulmonary function tests before marrow transplantation. , 1992, Chest.

[18]  D. Johns,et al.  Single breath carbon monoxide diffusing capacity (transfer factor) , 1988, The American review of respiratory disease.

[19]  John F. Murray,et al.  Textbook of Respiratory Medicine , 1988 .

[20]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[21]  F. Prime,et al.  Book Review: Ventilation/Blood Flow and Gas Exchange , 1966 .

[22]  K. Yamaguchi,et al.  Inhomogeneities of ventilation and the diffusing capacity to perfusion in various chronic lung diseases. , 1997, American journal of respiratory and critical care medicine.

[23]  R. J. Clark Carbon monoxide diffusing capacity. , 1977, Arizona medicine.